胃饥饿素受体 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-01-09. Where a claim depends on a specific study, the study is described rather than over-claimed.
At the receptor level, ipamorelin binds GHS-R1a and triggers signaling through Gq-coupled pathways. Activation leads to calcium release and downstream effects in pituitary somatotroph cells. These events promote the release of growth hormone into circulation. The response depends on the presence of the receptor and on the physiological state of the animal or tissue studied. Because the receptor is also found in other tissues, effects beyond the pituitary have been examined in laboratory models, though the extent of those effects remains an area of ongoing study.
One distinguishing feature reported in animal studies is selectivity. Ipamorelin stimulated growth hormone release with limited elevation of adrenocorticotropic hormone or cortisol compared with earlier secretagogues such as GHRP-6. This pattern has been described as more selective for the growth hormone axis. The finding comes mainly from preclinical work, and the degree to which it holds across species and doses is not fully settled. Reports also describe effects on gastric motility in animal models, suggesting activity outside the pituitary, though the clinical relevance of this observation is uncertain.
Ipamorelin is a synthetic pentapeptide that acts on the growth hormone secretagogue receptor, also known as the ghrelin receptor. Its sequence contains five amino acid residues, including a non-natural residue that increases stability against enzymatic breakdown. The compound was developed in the 1990s as part of research into small peptides that stimulate pituitary hormone release. Unlike larger protein hormones, it can be produced by solid-phase peptide synthesis and characterized by standard analytical methods.
Selectivity is the property most often attached to this peptide. Published animal and early human studies record increases in growth hormone release after administration, with adrenocorticotropic hormone and cortisol responses remaining small by comparison. Effects on appetite-related pathways also appear weaker than those reported for several earlier secretagogues. Reviews that compare members of the growth hormone secretagogue family cite these findings frequently, though the receptor-level explanation for the selectivity continues to be debated rather than settled.
Ipamorelin is a synthetic pentapeptide classified as a growth hormone secretagogue. Its sequence, Aib-His-D-2-Nal-D-Phe-Lys-NH2, combines three non-proteinogenic residues with a C-terminal amide. The N-terminal aminoisobutyric acid unit and the two aromatic D-amino acids distinguish it from peptides assembled only from standard L-amino acids. Its formula is C38H49N9O5, corresponding to an average mass near 711.9 Da. At neutral pH the molecule carries a net positive charge, a property that shapes its behaviour in chromatographic and electrophoretic systems.
The compound was developed at Novo Nordisk during the 1990s as part of a programme seeking secretagogues with improved selectivity. It was described in the peer-reviewed literature in 1998 alongside related pentapeptides from the same series. Investigators advanced it because it raised growth hormone output in animal models while leaving other pituitary hormones comparatively unaffected. The development code NNC 26-0161 appears in earlier reports, and ipamorelin later became the common designation in published work.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic pentapeptide | Chain of five amino acid residues |
| Molecular mass | Approximately 712 Da | Consistent with a five-residue chain |
| Receptor target | GHS-R1a | Growth hormone secretagogue receptor |
| Primary action | Growth hormone release | Pituitary somatotroph stimulation |
| Research origin | Developed in the 1990s | Small-peptide secretagogue program |
在机制层面，ipamorelin 与生长激素促分泌受体 1a 型结合，该受体也介导胃饥饿素的多种效应。受体激活后，细胞内信号促进生长激素从垂体前叶释放。由于对促肾上腺皮质激素和皮质醇的刺激较弱，它被视为选择性较高的促分泌剂。这种选择性在动物模型和少量人体研究中被观察到，但人体数据仍然有限。
现有文献多来自小规模、短期的研究，涉及生长激素缺乏、术后肠麻痹等方向。长期使用是否导致受体脱敏，以及重复给药后效应是否衰减，仍属开放问题。不同研究之间的剂量、给药途径和受试者特征差异较大，因此结论外推需谨慎。关于临床获益的确切证据尚不充分，需要更大规模的对照试验来澄清。
Structural features distinguish the molecule from earlier secretagogues. An alpha-aminoisobutyric acid residue near the N-terminus and a D-naphthylalanine substitution increase receptor affinity, while C-terminal amidation improves resistance to exopeptidases. These modifications are associated with reduced stimulation of appetite and of the hypothalamic-pituitary-adrenal axis compared with hexarelin or growth hormone releasing peptide-6. Whether the same profile applies at every dose level studied is a matter of ongoing investigation rather than settled consensus.
Ipamorelin is a synthetic pentapeptide that acts as an agonist at the ghrelin receptor, also called the growth hormone secretagogue receptor type 1a. Its sequence incorporates non-natural residues, which slows enzymatic breakdown relative to short native peptides. In laboratory and early clinical work the compound is described as a selective growth hormone secretagogue because it raises growth hormone with comparatively little effect on other pituitary outputs. The degree to which that selectivity holds across species and dosing regimens remains an open question in the published literature.
Storage recommendations for the dry solid center on low temperature and low moisture, most often -20 °C in a sealed, desiccated container protected from light. Solutions are less stable than the powder and are usually kept cold and used within a short window. Freeze-thaw cycling is a recognized source of loss, and aliquoting before freezing is a standard precaution. These practices derive from general peptide handling principles rather than from a single published stability trial, so exact shelf lives should be treated as approximate.
Analytical confirmation relies on reversed-phase high-performance liquid chromatography, often coupled to mass spectrometry for identity and purity assessment. Mass spectrometry distinguishes the intact molecule from truncation products and from oxidation or deamidation variants that share similar chromatographic retention. Immunoassays appear in some biological studies but can cross-react with related peptides, so they are weaker tools for identity work. Reported purity figures depend heavily on the gradient, detector, and integration method used, which complicates direct comparison between laboratories.
== Symptoms and signs == NAION typically presents suddenly upon awakening. The affected person notes seeing poorly in one eye. Vision in that eye is obscured by a dark shadow, often involving just the upper or lower half of vision, usually the area closer to the nose. There is no pain. Within approximately six months following the infarct, visual acuity improves by three or more lines of vision on the Snellen Chart (the chart with smaller letters on each lower line) in 42.7% of patients, while in 12.4% of patients, vision worsens by three lines. Opposite eye involvement occurs in approximately 15% to 20% of patients with NAION within 5 years. It is not always devastating as visual acuity may remain only moderately impaired. Furthermore, most cases of NAION involve the loss of a hemifield (either the upper or lower half of the visual field, but not both). A few cases of NAION involve near-total loss of vision.
=== Injection valve === The injection valve is a motorized valve which links the mixer and sample loop to the column. Typically the valve has three positions for loading the sample loop, for injecting the sample from the loop into the column, and for connecting the pumps directly to the waste line to wash them or change buffer solutions. The injection valve has a sample loading port through which the sample can be loaded into the injection loop, usually from a hypodermic syringe using a Luer-lock connection.
=== Radiation protection associations === The Association of German Radiation Protection Physicians (VDSÄ) was formed in the late 1950s from a working group of radiation protection physicians of the German Red Cross and was founded in 1964. It was dedicated to the promotion of radiation protection and the representation of medical, dental, and veterinary radiation protection concerns to the public and the health care system. In 2017, it was merged into the Professional Association for Radiation Protection. The Austrian Association for Radiation Protection (ÖVS), founded in 1966, pursues the same goals as the Association for Medical Radiation Protection in Austria. The Professional Association for Radiation Protection for Germany and Switzerland is networked worldwide.
== Function == Microproteins function as post-translational regulators. Microproteins disrupt the formation of heterodimeric, homodimeric, or multimeric complexes. Furthermore, microproteins can interact with any protein that requires functional dimers to function normally. The primary targets are transcription factors that bind to DNA as dimers. Microproteins regulate these complexes by creating homotypic dimers with the targets and inhibit protein complex function. The two types of miP inhibitions are: homotypic miP inhibition and heterotypic miP inhibition. In homotypic miP inhibition, microproteins interact with proteins with similar protein-protein interaction (PPI) domain. In heterotypic miP inhibition, microproteins interact with proteins with different but compatible PPI domain. In both types of inhibition, microproteins interfere and prevent the PPI domains from interacting with their normal proteins. Microproteins plays roles in biological process such as immunity and inflammation, cancer and cell cycle regulation, cellular transport, muscle and heart functions, gene expression and genome maintenance, proteostasis, and metabolic homeostasis.
Avenir Suisse, founded in 1999 by fifteen of the largest Swiss companies. It is supported by over 130 companies to date. DCAF, the Geneva Centre for the Democratic Control of Armed Forces, founded in 2000 to research security sector governance and reform. Gottlieb Duttweiler Institute (GDI), conceived by Migros-founder Gottlieb Duttweiler in 1946. Horasis, which hosts the annual Horasis Global Meeting Liberal Institute, founded in 1979.
Sources: en.wikipedia.org
=== False correspondence with vaporization === Vaporization (from liquid to gas) is divided into two types: vaporization on the surface of the liquid is called evaporation, and vaporization at the boiling point with formation of bubbles in the interior of the liquid is called boiling. However there is no such distinction for the solid-to-gas transition, which is always called sublimation in both corresponding cases.
== Revival == The African Renaissance has been taken up as part of the International Decade for People of African Descent from 2015 to 2024, in which the Door of Return Initiative seeks to bring members of the African diaspora back to the continent. The initiative is spearheaded by the historical Maroon community of Accompong, Jamaica, in cooperation with Nigeria, Ghana, and Zimbabwe.
Similarly, researchers from the Technical University of Munich and LMU Munich have developed a method to have T-cells target tumor cells by using antigen coated DNA origami. The researchers developed a method to create chassis known as programmable T-cell Engagers (PTEs) which are DNA origami structures that can be configured to bind to user-defined target cells and T-cells based on which antigens are coated on the surfaces of the nanostructure. The in vitro results show that after 24 hours of exposure 90% of the tumor cells were destroyed. Meanwhile, in vivo testing showed that their PTEs were capable of binding to the target proteins for several hours which validates the mechanism they designed.
Charles N. McEwen; Barbara S. Larsen (1997) Electrospray ionization on quadrupole and magnetic-sector mass spectrometers, in Electrospray ionization mass spectrometry: fundamentals, instrumentation, and applications. Richard B. Cole (Ed.) Wiley. 177–202. Sarah Trimpin; David E. Clemmer; Barbara S. Larsen (2010) Snapshot, Conformation, and Bulk Fragmentation of Polymeric Architectures using ESI–IMS–MS, in Ion Mobility Spectrometry–Mass Spectrometry: Theory and Applications. CRC Press. 215–235.
Sources: en.wikipedia.org
It acts on the growth hormone secretagogue receptor, GHS-R1a, which is also the receptor for ghrelin. Binding triggers intracellular signaling that promotes growth hormone release from the pituitary. The interaction is the basis for its classification as a secretagogue.
In animal studies it showed greater selectivity for growth hormone release, with less effect on cortisol and adrenocorticotropic hormone than compounds such as GHRP-6. This selectivity is one of the most frequently cited features in preclinical literature. Whether the same profile applies in other contexts is not fully established.
The receptor-level events are reasonably well described, but the full range of downstream effects is not. Studies have reported activity in tissues beyond the pituitary, including the gut. How these observations translate across species and conditions remains an open question.
It is a synthetic five-amino-acid peptide that acts as a growth hormone secretagogue. Three of its residues are non-standard amino acids, and the chain ends in an amide rather than a free acid. The molecule is small enough that it can be characterised by routine peptide analytical techniques.